Monte Rosa Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Monte Rosa Therapeutics, Inc. (GLUE) reported Increase (Decrease) in Accounts Receivable of $0 for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-08-07
- 2025-06-30: Increase (Decrease) in Accounts Receivable 6 month $0.00.
- 2024-06-30: Increase (Decrease) in Accounts Receivable 6 month $9.00M.
- 2023-06-30: Increase (Decrease) in Accounts Receivable 6 month $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 6 month |
|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2024-06-30 | $9.00M 10-Q · filed 2025-08-07 |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |